

A Vista Partners Interview with Steve Shum CEO of INVO Bioscience Regarding Increasing Access to Care for Fertility Treatment

Currently, it is estimated that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated

SARASOTA, Fla., June 19, 2020 /PRNewswire/ — Today, Steve Shum, Chief Executive Officer of INVO Bioscience, Inc. (OTCQB: INVO) (OTCQB: INVOD), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, was interviewed by Vista Partners LLC's Managing Partner John F. Heerdink, Jr. regarding the role INVOcell plays in increasing access to care for fertility treatment.



See the complete interview at the Vista Partners LLC website [here](#).

About INVO Bioscience

We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary *in vivo* method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural *in vivo* incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit <http://invobioscience.com/>

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future

operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at **www.sec.gov**. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

 View original content to download

multimedia:<http://www.prnewswire.com/news-releases/a-vista-partners-interview-with-steve-shum-ceo-of-invo-bioscience-regarding-increasing-access-to-care-for-fertility-treatment-301080100.html>

SOURCE INVO Bioscience, Inc.